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ABSTRACT-We report on 2 patients, one female and one male transsexual; in both, 
Type III stress urinary incontinence developed after gender reassignment surgery. Both 
patients were treated by periurethral injection of gluteraldehyde cross-linked collagen re- 
sulting in a marked symptomatic improvement in association with a significant rise in ab- 
dominal leak point pressures. We believe these are the first reported cases of collagen in- 
jection being used for urinary incontinence after gender reassignment surgery. 
The reported prevalence of transsexualism 
varies between 1:25,000 and l:lOO,OOO with a re- 
ported male:female ratio of between 5:l and 
20: 1. lw3 Considerable controversy exists regarding 
the indications for gender reassignment surgery as 
well as the various surgical techniques used. For 
patients undergoing this type of surgery, specific 
postoperative complications include graft infec- 
tion, fistula formation, urethral and neovaginal 
stenosis, impotence, and continuing psychosexual 
dysfunction. 4-7 Although urethral and vesical fis- 
tulas appear to be the most common cause of uri- 
nary incontinence, the urethral sphincteric mech- 
anism also may be disrupted as a result of surgery. 
Twenty years ago, polytef was introduced for the 
treatment of stress urinary incontinence.8,9 Subse- 
quent long-term follow-up has lead to concern of 
particle migration and long-term results.lO-l2 Peri- 
urethral collagen has been used successfully for 
the treatment of patients with intrinsic sphincter 
dysfunction without associated morbity.13 
Collagen, a glutaraldehyde cross-linked bovine- 
derived material has been the subject of a multi- 
center study 14-18 Briefly, the material produces a 
significant increase in the ability of the urethra to 
withstand abdominal pressure as an expulsive 
force.19,20 In a three-year follow-up period, 80 per- 
cent of patients who became continent after colla- 
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gen injection remained continent.17 The primary 
indication for use of the material is poor intrinsic 
urethral closing function associated with leakage 
at low to very low abdominal pressures.21-23 In fe- 
males, this type of incontinence is associated with 
a fixed urethral position and leakage at abdominal 
pressures less than 60 cm of water.*O In males, in- 
continence after prostatectomy leakage occurs at 
abdominal pressures less than 100 cm of water.18 
We report on 2 transsexual patients, one female 
and one male; in both severe stress incontinence 
developed after gender reassignment surgery. Both 
patients were treated by periurethral injection of 
gluteraldehyde cross-linked collagen resulting in 
marked symptomatic improvement in association 
with a significant rise in abdominal leak point 
pressures. We believe these are the first reported 
cases of collagen injection being used for urinary 
incontinence after gender reassignment surgery 
CASE REPORTS 
CASE I 
A thirty-five-year-old female transsexual with 
severe stress urinary incontinence was referred to 
the University of Michigan Medical Center. The 
patient had undergone gender reassignment 
surgery over three years previously. This included 
a colpohysterectomy, adnexectomy, bilateral mas- 
tectomy, phalloplasty (using a rectus abdominis 
muscle graft), and urethra transposition. Nu- 
merous postoperative complications developed 
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FIGURE 1. Abdominal leak point pressure of 28 cm 
water in female transsexual after gender reassignment 
surgery. 
including recurrent urethrocutaneous fistulas, 
urethral diverticula, urethral calculi, meatal steno- 
sis, and severe stress urinary incontinence. Fur- 
ther reconstructive procedures were performed in- 
cluding a gracilis myocutaneous graft to the site of 
recurrent fistula formation, perineal urethroplasty, 
and bladder neck needle suspension. The patient 
remained incontinent, voiding urine through the 
site of the original urethral meatus. Fluorourody- 
namic evaluation revealed severe Type III stress 
urinary incontinence with a widely open bladder 
neck and an abdominal leak point pressure of 28 
cm water (Fig. 1). Over the following eighteen 
months, this patient underwent cystoscopic 
transurethral collagen injection on four occasions. 
A total of 70 cc of collagen was used. Ten months 
after the last treatment, her leak point pressure is 
in excess of 128 cm water. She enjoys a significant 
symptomatic improvement, only wearing a pad 
during jogging for minimal stress urinary inconti- 
nence. 
0s~ 2 
A thirty-seven-year-old male transsexual pre- 
sented with stress urinary incontinence, having 
undergone gender reassignment surgery more 
than three years previously This included bilateral 
breast augmentation, bilateral orchiectomy, penec- 
tomy, urethral transposition, and vaginoplasty 
using invaginated penoscrotal flaps. Postoperative 
complications included graft infection, vaginal 
stenosis, and urinary incontinence. The patient 
was maintained on continuous oral estrogen. Flu- 
orourodynamic evaluation revealed Type III stress 
urinary incontinence with a leak point pressure of 
87 cm water (Fig. 2). Digital rectal examination 
FIGURE 2. Abdominal leak point pressure of 87 cm 
water in male transsexual after gender reassignment 
surgery. 
revealed an atrophic prostate gland. This patient 
subsequently underwent cystoscopic transurethral 
collagen injection on two occasions. A total of 25 
cc of collagen were used. Seven months after the 
last treatment, this patient complains only of mild 
urge urinary incontinence. Repeat fluorourody- 
namic assessment reveals a leak point pressure of 
126 cm water. 
COMMENT 
Direct urethral sphincter injury and denervation 
are the probable causes of Type III stress urinary 
incontinence in both patients reported. In the 
male transsexual patient, estrogen-induced 
prostate atrophy may be an additional factor con- 
tributing to incontinence. Surgical correction of 
Type III stress urinary incontinence requires either 
sling suspension of the bladder neck or artificial 
sphincter insertion. 24.25 Anatomic distortion and 
tissue fibrosis in these cases would render these 
procedures both technically difficult and poten- 
tially hazardous. 
Injectable collagen has been available since 
1983 and was initially used in plastic surgery.26 
Studies revealed that the majority of collagen was 
reabsorbed in ninety days.27 Since that time, colla- 
gen has been cross-linked with gluteraldehyde 
which in human studies seems to provide a ma- 
trix for the ingrowth of host collagen providing a 
more permanent urethral coaptation.‘R,28 
The results of multicenter trials suggest that 
glutaraldehyde cross-linked collagen maintains a 
urethral continence effect against abdominal pres- 
sure for periods up to two years after injec- 
tion.‘7~1*~20~21 The effect is objectively measured by 
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determining the amount of abdominal pressure re- 
quired to induce urinary leakage prior to and fol- 
lowing collagen injection. That measurement is 
the most valid method to assess the strength of 
the urethral sphincter vis a vis abdominal pres- 
sure. Collagen injection provided a significantly 
lower risk therapeutic option for the patients de- 
scribed in this report. Both tolerated the proce- 
dure well and were satisfied with the outcome. Al- 
though the indications and techniques of gender 
reassignment surgery remain subjects of contro- 
versy, periurethral collagen injection appears to 
have a role in the treatment of urinary inconti- 
nence arising after such surgery. 
Stanley J. Swierzewski, Ill, M.D. 
Catherine Horan Medical Building 
1221 Main Street 
Holyoke, Massachusetts 01040 
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